The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face competition from cheaper generics.
The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face competition from cheaper generics.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.